Nasus Pharma (NSRX) Assets Average (2025)
Nasus Pharma's (NSRX) quarterly Assets Average came in at $2.8 million in Q4 2025, up 316.15% on a QoQ basis from $678000.0 in Q2 2025.
Nasus Pharma (NSRX) Assets Average (2025) Analysis & Trends
Nasus Pharma (NSRX) has 1 years of Assets Average data on file, last reported at $2.8 million in Q4 2025.
- Quarterly Assets Average changed N/A year-over-year to $2.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.8 million (changed N/A YoY) and the FY2025 annual result came in at $2.9 million, changed N/A from the prior year.
- Assets Average improved to $2.8 million in Q4 2025, from $678000.0 in the prior quarter.
- In the past five years, Assets Average ranged from a high of $2.8 million in Q4 2025 to a low of $678000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 200.98 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | 135.79 Bn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | 129.24 Bn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | 114.92 Bn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 94.07 Bn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | 52.82 Bn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 204.57 Bn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | 83.80 Bn |
| 10 | Nasus Pharma | 30.76 Mn | 30.76 Mn | - | 2.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.82 Mn |
| Jun 30, 2025 | 678,000.00 |